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Combination chemotherapy (CC) deserves credit for the increase in survival for patients with 
limited small cell lung cancer (SCLC). However, the best CC is not clearly established. The 
definition of limited disease and the work-up to define limited disease has evolved over the last 
20 years. Imaging studies are now more sophisticated (MRI and CT scan) and used more fre- 
quently. Although there is general agreement on what constitutes limited disease and what is 
not, the extent of the staging work-up, the issue of ipsilateral pleural effusion and supraclavicu- 
lar disease continue to stimulate lively discussion. 
The last decade’s studies usually employed cyclophosphamide-based CC. Presently. plati- 
num-etoposide (PE) CC is assuming increased importance at least in North America. However, 
in limited disease, no data compare the regimens directly. 
Integration of CC with thoracic radiotherapy (TRT) has warranted much attention. These is- 
sues have been addressed in 3 recent reviews [l-33. Three randomized North American studies, 
the SEG [4], the NCI-USA [5], and the CALGB [63, all support a survival benefit for the group 
receiving TRT. However, the British Medical Research Council (MRC) [7], the Finsen Institute 
[8] and the later Southeastern Cancer Study Group (SEG) trial did not show improvement for 
the TRT group. For all of these trials, the CC was cyclophosphamide-based, but the radiother- 
apy varied in many ways. 
TRT has been known to produce dramatic regression of primary tumors in SCLC. The failure 
of CC to durably control the bulk primary location and TRT’s local efficacy both suggested 
their combination. Comis reported local failure in 50-100% of cases [9]. 
The method of CC-TRT is another factor that influences toxicity for sure and may also be 
important in efficacy and survival, but the available information prevents reaching conclusions. 
There are major problems that interfere with retrospective literature analysis of this issue. 
The term‘local control’ is quite imprecise. Assessment of local control in most series has been 
based on clinicians’ assessment of chest X-rays. More recently bronchoscopy and CT-scanning 
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have also been included. However, selected cases have been subjecti to these expensive and 
invasive tests. Moreover, definition of ‘chest failure’ commonly includes distant chest sites - 
contralateral lung, ipsilateral, parenchymal, and pleural-based densities or effusions. Further- 
more, in patients failing at distant sites, attention to local control or failure was likely to be less 
carefully detailed. Separating the evaluation of failure pattern into ‘lung only’ and ‘local plus 
distant’, if accurate, focuses on whether better local treatment or better systemic treatment is 
more important. Those with systemic failure have no prospect for improvement with local mo- 
dalities. 
Local failure data commonly report failure fmm response. It is not clear how patients with 
less-than complete response are handled. When treatment regimens have varied response rates, 
the proportion failing initial treatment and the proportion that fail after initial response are quite 
different. The term ‘local control’ is applied to all patients, but ‘local failure’ is commonly ap- 
plied only after failure from response, but these terms are not used uniformly. Furthermore, 
studies with short median survival or few 2-year survivors may overestimate local control. 
Determination of local status can be quite subjective in patients receiving TRT. Thus, future 
trials need to study the endpoint of local control recognizing the above pitfalls and then design 
studies that can clarify these issues. 
If the issue of excessive local failure is important, optimizing TRT may yield results. Defin- 
ing (1) volume, (2) course, (3) dose, (4) duration of therapy, as well as integration with systemic 
therapy are all issues that have received surprisingly little attention. These variables certainly 
may influence local control and possibly survival. Table 1 presents the local control reported 
from 10 recent studies. 
These studies were selected because they reported local failure or control. In the 4 contmlled 
studies, TRT reduced local failure on each study. With CC alone local failure ranged between 
40% and 82%; with the addition of TRT it ranged between 18% and 69%. 
Volume, course, dose 
Prechemotherapy vs post-chemotherapy TRT volume is a topic of discussion in other dis- 
eases. For concurrent methods, the initial volume is the pre-chemotherapy volume. With the al- 
ternating strategy, the subsequent courses can often have reduced volumes, but no study reports 
the influence of either maintaining a large volume or reducing it after response. The sequential 
method is the setting to evaluate this. Using larger volumes versus smaller or tighter volumes is 
another issue. Understanding the physics of field borders and the lymphatic spread of lung m- 
mors has caused TRT field sires to increase. Radiating larger field sixes necessarily increases 
dose to normal tissues, which potentially increases toxicity, particularly in conjunction with CC. 
Table 2 demonstrates the influence of larger versus smaller volumes as described in these 
studies. Custom shields or blocks and techniques to maximize tumor dose and minimize normal 
tissue dose warrant attention. Posterior spinal shields inadvertently protect the mediastinum, and 
this may cause local failure. The merit or folly of larger field sixes is unknown. 
Continuous course is thought to be better than split-course because it prevents the regrowth 
of surviving tumor cells between courses. Very few facts bolsters this theory. The alternating 
strategy requires split-courses. However, effective chemotherapy may prevent or inhibit prolife- 
ration of tumor cells between courses. 
Dose can be quite difficult to sort out because the biological equivalent dose of different 
fractionation schemes is poorly expressed in rad. Gray (Gy) or other physical units. The effects 
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on acme-effect tissue (tumors, bone marrow, mucosa) may not be paralleled in late-effect time 
(brain, lung). NSD and cr&ratio models need further testing. The influence of time and chemo- 
therapy on these variables may be quite important, but arc presently poorly understood. As a 
general rule, fraction sizes greater than 2 Gy are more harmful to late-effect tissue, but kill more 
acute tissue per session. Conversely, fraction sire less than 2 Gy respect late tissue, but kill 
fewer acute effect tissues per session. Simply comparing total doses amongst reported studies 
can be quite misleading. With this in mind, Table 3 describes the reported failure by total dose. 
Table 1 
Limited small ceil lung cancer iocai failure 
StYpfflCCi GtWp/ItlSt ChemO cc C+TRT 
Mixed MGH V 32% 
sequential Memorial A 35% 
Yale B 3.8% 
Alternating IGR A 25% 
SEG B 42 23% 
Concurrent SEG B(A)* 40 18% 
CALGB B 82 37-69% 
NCI B 67 29% 
SWOG A 29% 
Pm A 4% @um) 
100% (var.) 
V--varied -most cyclophosphatnide-based, some used platin~-baskd; A=platinum-based; B=cyclophosphamide- 
based. 
Y?nd randomization for responders to: ItA. 
Table 2 
Intluence of volume 
L4uge volume: CALGB 2a42 
SWGG 29 
Small volume: Pm 16 
Highlighted studies 
Choi retrospectively analyzed 207 patients from the Massachusetts General Hospital between 
1974 and 1977 1101. The TRT dose ranged from 30 to 40 Gy in the early years, and after 1978 
the TRT dose increased from 44 to 52 Gy. Doses of 30 and 35 Gy had a failure of 100% and 
79%, respectively. The TRT doses between 45 and 50 Gy had local failure of 39% and 36%. re- 
spectively. The dose 40 Gy has a local failure of 43%. The authors suggested that these data 
show a ‘dose-response’ relationship. Details regarding volume, pre- or post-CC, total time of 
ueatment and method of integration of TRT and CC were not discussed. These data were col- 
lected over a decade, with changes in staging, CC and dose, but the univariate analysis evalu- 




Yale 1111 used cytoxan, etoposide and methotrexate, an infrequently used CC regimen, for 3 
cycles followed by splitcourse TRT (60 Gy/6 weeks/3 Gy/fraction). The local failure was only 
3.8%. However, 42% had less than CR, %-year survival was ~30%. Duration of follow-up 
(minimum or median) was not mentioned. Only 7/26 patients remained alive. We know one 
local failure (? from CR), but status of the other 25 patients remains in doubt, and durability of 
the local control in the 7 survivors mmains in question. TRT volume, pre- or post-chemother- 
apy, use of spinal cord blocks, and methods of assessment of local control were not discussed. 
Furthermore, ultimate local control, as opposed to first failure, would be noteworthy. 
The Memorial Sloan-Kettering developed the PE regimen, alternated it with CAV, prior to 
45 Gy continuous course, 4 days/week using 2.5 Gy fractions. The target volumes were deter- 
mined by CT scan, using multiple-field techniques (3 fields, some laterals). Whether volumes 
were pre- or post-chemotherapy was not reported. Of 34 patients, 12 achieved CR (35%) and 18 
achieved PR (53%) after CC, and increased to 65% CR and 26% PR after TRT. Four failed in- 
field, 3 outside the field and 2 both. Local failure was 292, and local control was 65% (22/34). 
However. there were 9 local failures, but it is not clear what denominator is appropriate. Since 
the initial CR rate to chemotherapy was only 35% and 65% after TRT, longer follow-up may 
have yielded more locoregional failures, but that data was not provided. 
Table 3 
Influence of dose In local failure: selected series 
Dose Institution W%) 
-SKI MGH 79-100 

















The first SEG and the Institute Gustave Roussy (IGR) both used CC on week 1 of cycles fol- 
lowed by large fraction (2.5-3.0 Gy), split-course TRT to total doses of 40 Gy (weeks 58 and 
11) for the SEG trial and 45-55 Gy (weeks 6. 12, 15) for the IGR. The SEG trial was ran- 
domized, the CC group failed in 42% but the TRT group failed in 23%. The IGR reported 12% 
failure in the chest alone, but 25% in chest plus other sites. The technical factors were not dis- 
cussed by the SEG, but the IGR did boost off cord for 15 Gy with lateral or angled fields. 
Concurrent trials 
The second SEG, Cancer and Leukemia Group B (CALGB), and National Cancer Institute 
@ICI) all used cyclophosphamide-based CC and concurrent TRT. The NC1 and CALGB used 
continuous courts for 3 and 5 weeks, respectively, but the SEG used split-course with TRT ad- 
ministered in 3 Gy fractions during weeks 1,2 and 4. The NC1 used 40 Gy in 3 weeks (2.66 
Gy/fraction) and wide posterior spinal cord shields. Failure in the chest was recorded at 67% for 
the CC group versus 29% for the TRT group. Variant histology was excluded from the NC1 
trial. The CALGB used 50 Gy in 5 weeks (2.0 Gy/fraction), using a large volume technique, 
which included the entire mediastinum plus the supraclavicular fossa. There were 3 arms: (1) 
immediate TRT; (2) delayed TRT, and (3) not TRT. The chest-only and chest plus distant me- 
tastasis (DM) was: (1) 28% and 37%; (2) 42% and 69%; and (3) 67% and 82%. The concurrent 
SEG trial used 45 Gy during the first two CAV cycles. The addition of TRT did not improve 
survival. A subsequent randomization to PE improved survival in those randomized. The local 
failure of this trial was 40% in the CC group versus 18% in arms randomized to TRT. A retro- 
spective comparison between the SEG alternating and concurrent trials showed a local and DM 
of 22% versus 35%. respectively, P=O.Ol; however, there was no difference for local only [ 121; 
Concurrent PE and TRT 
The Southwest Oncology Group (SWGG) and University of Pennsylvania (Penn) have both 
used PE regimens (not identical) and 45 Gy TRT. The SWGG gave 45 Gy in 5 weeks. The 
SWGG trial used generous fields with 2-2.5 cm margins including the entire mediastinum, con- 
tralateral hilum and both supraclavicular fossae. The off-cord technique is not described. Penn 
gave 45 Gy in 3 weeks using 1.5 Gy fractions Bid, CT planning and avoiding direct posterior- 
spinal cord blocks. Penn’s fields were ‘tight’ with a margin of 1.0-1.5 cm. Average field size 
was 13.5x16.5 (range 11-17.5 cm x 12-26.5 cm). The contralateral hilum was never treated. 
Only 45% had ipsilateral supraclavicular fossa treated. The SWGG will report on 154 patients 
with 12% chest or chest and brain failure, but 26 less than PR patients (17%) are not scored as 
failures. The Penn trial had only 2/31 (6%) with less than CR. With a median follow-up of 42 
months, 5/31 (16%) have failed locally. All had variant histology (415 presented with variant 
histology). For pure SCLC, the total failure was 4% (l/27), and zero for those receiving full 
dose TRT. 
In conclusion, studies vary in how they report local control and failure. Although multiple 
variables may be important, most authors isolate variables chosen for discussion. No convincing 
data points to a dose-response relationship above 40 Gy. The issue of sequence and type of CC 
are linked to this issue; definitively for toxicity, but probably response too. There are no studies 
addressing pre- versus postchemotherapy volume or large volume vs small volume. Technique 
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of lung and spinal cord protection influence results, but no study specifically addressed this 
issue. The larger volume, larger dose, larger margin studies do not appear to have better survival 
or local control than the small study, which intentionally avoids the supraclavicular and contra- 
lateral hilar nodes. 
These issues would probably not warrant a prospective trial, but carefully designed trials can 














Turrisi, A.T. (1988) The role of radiotherapy for bmited small cell lung cancer. Oncology, 2: 19-25. 
Turrisi. A.T. (1988) Combined-modality tmatment of brtkited small cell lung -r. Adv. Oncol., 4: 17-25. 
Turrisi, A.T. (1989) combined-modality therapy for limited small cell lung cancers a decade of improvement In: 
SmaR Cell Lung Cancer and Non SmaJl Cell Lung Cancer. (R.J. Gralla and LH. J&horn eds.). Royal Society of 
Medicine Services, pp. 53-61. 
Perez, C.A., Rinhom. L, Oldham, R.K. et al. (1984) Randomized traiJ of radiotherapy to the thorax in limited 
small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a prehminaty 
report. I. Chn. Oncol., 2: 12m12O8. 
Bunn. P.A.. Jr., Lichter, A.S.. Makuch. R.W. et al. (1987) Chemotherapy alone or chemotherapy with chest radia- 
tion therapy in limited stage small cell hmg cancer. Arm. Intern. Med., 106: 655-662. 
Perry, M.C.. Eaton, W.L and Propett. K.J. (1987) Chemotherapy with or without radiation therapy in limited 
smakell carcinoma ofthehmg. N. Engl. J. Med., 316: 912-918. 
Souhami. RL., Geddes. D.M., Spiro, S.G. et al. (1984) Radiotherapy in smaU ceR cancer of the lung treated with 
ccmbination chemotherapy: a controkd trial. Br. Med. J.. 288: 1643-1646. 
0sterbnd. K., Hansen, H.H.. Hansen, H.S. et 1 (1986) Ckxnotherapy versus chemotherapy plus irradiation in 
small cell lung cancer. Results of a conttolled trial with five years follow-up. Br. J. Cancer, 54: 7-17. 
Comis. R.L (1982) SmaU cell ca rcinoma of the lung. Cancer Treat. Rev. 9: 237. 
Choi. N.C. and Carey, R.C. (1987) Loco-regional faihrre rate in relation with radiation dose in combined modality 
approach of multiagent chemotherapy and mdiothempy for limited stage smah-cell lung carcinoma Jnt. J. Radiat. 
Oncol. Biol. Phys.. 13 (Suppl. 1): 188. 
Papac. R.J., Son. Y., Bien. R. et al. (1987). Improved local control of thorn& disease in smah ceJl lung cancer with 
higher dose thomcic irradiation and cyclic chemotherapy. Jnt J. Radiat. OncoL Biol. Phys.. 13: 993-998. 
Birch, R, Omum, G., Greco, F.A. et al. (1988). Patterns of faihue in ccmbkd chemothempy and mdiothempy for 
limited small cell lung cancer: Southeastern Cancer Study Group experience. NCJ Mcmogr.. 6: 265-270. 
135 
